Are progranulin levels associated with polycystic ovary syndrome and its possible metabolic effects in adolescents and young women?

Archives of Gynecology and Obstetrics

Volumn 294, Issue 2, 2016, Pages 403-409

  Ersoy, Ali Ozgur ^a   Tokmak, Aytekin ^a   Ozler, Sibel ^a   Oztas, Efser ^a   Ersoy, Ebru ^a   Celik, Huseyin Tugrul ^b   Erdamar, Husamettin ^b   Yilmaz, Nafiye ^a  

^a Zekai Tahir Burak Women's Health Training and Research Hospital   (Turkey)

^b TURGUT OZAL UNIVERSITY   (Turkey)

Author keywords

Cardiovascular diseases; Growth factor; Marker; Polycystic ovary syndrome; Progranulin

Indexed keywords

C REACTIVE PROTEIN; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGRANULIN; TESTOSTERONE; GRN PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN; SIGNAL PEPTIDE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; INSULIN SENSITIVITY; LUTEINIZING HORMONE FOLLICLE STIMULATING HORMONE RATIO; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PHYSICAL PARAMETERS; PROTEIN DETERMINATION; PROTEIN FUNCTION; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; INSULIN RESISTANCE; METABOLISM; OBESITY; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPROTEINS, HDL; METABOLIC SYNDROME X; OBESITY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; RISK FACTORS; TESTOSTERONE; YOUNG ADULT;

EID: 84963649313     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-016-4096-8     Document Type: Article

References (32)

1. Azziz R, Carmina E, Dewailly D et al (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91:456–488
2. Nestler JE, Jakubowicz DJ, de Vargas AF et al (1998) Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83:2001–2005
3. Diamanti- Kandarakis E, Papavassiliou AG, Kandarakis SA et al (2007) Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 18:280–285
4. Ryan CL, Baranowski DC, Chitramuthu BP et al (2009) Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neurosci 10:130
5. Suzuki M, Matsumuro M, Hirabayashi K et al (2000) Oocyte-specific expression of granulin precursor (acrogranin) in rat ovary. J Reprod Dev 46:271–277
6. Fauser BC, Tarlatzis BC, Rebar RW et al (2012) Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97(28–38):e25
7. Yildiz BO, Bolour S, Woods K, Moore A, Azziz R (2010) Visually scoring hirsutism. Hum Reprod Update 16:51–64
8. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR (2009) Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome. Gynecol Endocrinol 25:335–343
9. Cook S, Auinger P, Li C et al (2008) Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999–2002. J Pediatr 152:165–170
10. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
11. Celik Y (2007) Biostatistics, principles of research, 2nd edn. Dicle University Press, Diyarbakir
12. Baba T, Hoff HB 3rd, Nemoto H et al (1993) Acrogranin, an acrosomal cysteine-rich glycoprotein, is the precursor of the growth-modulating peptides, granulins, and epithelins, and is expressed in somatic as well as male germ cells. Mol Reprod Dev 34:233–243
13. He Z, Ong CHP, Halper J, Bateman A (2003) Progranulin is a mediator of the wound response. Nat Med 9:225–229
14. Brown Jones M, Michener CM, Blanchette JO et al (2003) The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res 9:44–51
15. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA (1998) Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 101:2622–2629
16. Wang J, Van Damme P, Cruchaga C et al (2010) Pathogenic cysteine mutations affect progranulin function and production of mature granulins. J Neurochem 112:1305–1315
17. Hsueh AJ, Kawamura K, Cheng Y, Fauser BC (2015) Intraovarian control of early folliculogenesis. Endocr Rev 36:1–24
18. Wild RA, Rizzo M, Clifton S, Carmina E (2011) Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 95(1073–9):e1–e11
19. Glueck CJ, Morrison JA, Goldenberg N, Wang P (2009) Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism 58:714–721
20. Legro RS, Kunselman AR, Dunaif A (2001) Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111:607–613
21. Essah PA, Nestler JE, Carmina E (2008) Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome. J Endocrinol Invest 31:35
22. Barter P, Gotto AM, LaRosa JC et al (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:1301–1310
23. Silfen ME, Denburg MR, Manibo AM et al (2003) Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 88:4682–4688
24. Berenson GS, Srinivasan SR, Bao W et al (1998) Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 338:1650–1656
25. Toulis KA, Goulis DG, Mintziori G et al (2011) Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 17:741–760
26. Türkçüoğlu I, Kafkasli A, Meydanli MM, Ozyalin F, Taşkapan C (2011) Independent predictors of cardiovascular risk in polycystic ovarian syndrome. Gynecol Endocrinol 27:915–919
27. Cheng Q, Xia W, Yang S et al (2013) Association of serum pigment epithelium-derived factor with high-sensitivity C-reactive protein in women with polycystic ovary syndrome. J Endocrinol Invest 36:632–635
28. Keskin Kurt R, Okyay AG, Hakverdi AU et al (2014) The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case-control study. Arch Gynecol Obstet 290:315–319
29. Okura H, Yamashita S, Ohama T et al (2010) HDL/apolipoprotein A-I binds to macrophage-derived progranulin and suppresses its conversion into proinflammatory granulins. J Atheroscler Thromb. 17:568–577
30. Matsubara T, Mita A, Minami K et al (2012) PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab 15:38–50
31. Bayram F, Kocer D, Ozsan M, Muhtaroglu S (2012) Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. Gynecol Endocrinol 28:497–501
32. Köninger A, Koch L, Edimiris P et al (2014) Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome. Arch Gynecol Obstet 290:1023–1030